Trump Secures 9 More Deals To Lower US Drug Prices

By Mintesinot Nigussie  |  September 1, 2026

US President Donald Trump has secured agreements with nine additional pharmaceutical companies to lower prescription drug prices, expanding his administration’s most-favoured-nation pricing programme to 26 drugmakers.

The latest agreements cover Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB, according to the White House.

The administration said the agreements will give every state Medicaid programme access to most-favoured-nation prices on medicines supplied by the nine companies. The drugs cover treatments for conditions including cancer, haemophilia, Parkinson’s disease, glaucoma, macular degeneration and liver disease.

The programme links US drug prices to the lowest prices paid by other developed countries. The White House said the 26 agreements now cover 89 percent of the US branded drug market.

The nine companies have also committed at least 19.6 billion US dollars collectively to US manufacturing in the near term, as the administration seeks to strengthen domestic pharmaceutical supply chains.

Several of the companies will contribute active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve. UCB will provide 163 tonnes of levetiracetam, while Sun Pharma will contribute 71.4 tonnes of clindamycin and 6.75 tonnes of doxycycline.

Teva will contribute 45 tonnes of metronidazole and 4.8 tonnes of amlodipine, while Astellas will provide 25 kilograms of tacrolimus.

The White House said patients had saved more than 700 million US dollars on medicines through TrumpRx since its launch in February 2026. It added that more than 500,000 senior citizens had saved a combined 216 million US dollars through a programme providing access to selected obesity medicines for 50 US dollars a month.

The Council of Economic Advisers estimates that the administration’s most-favoured-nation agreements could generate 600 billion US dollars in savings over the next decade, according to the White House.

Trump launched the policy in May 2025 through an executive order directing the administration to pursue drug prices in the US that align with the lowest prices paid by comparable developed countries.

The administration reached its first agreement with Pfizer in September 2025 and subsequently expanded the programme to other major pharmaceutical companies. The latest agreements bring the list to 26 companies.

The agreements also require participating manufacturers to offer most-favoured-nation pricing on new innovative medicines they bring to market, according to the White House.

Source: FSX Business News